Objective To measure patterns of clinical activity at colposcopy before and after vaccinated women entered the Scottish Cervical Screening Programme (SCSP).
Introduction
Immunisation against the two human papillomavirus (HPV) genotypes, 16 and 18, promises a substantial reduction in high-grade cervical intraepithelial neoplasia (CIN) by 67% and cervical cancers by 70%. 1 These predictions assume high vaccine uptake and the maintenance of existing cervical screening. Data from Australia indicated a significant decrease in high-grade cervical cytology in women vaccinated before the age of 18 years. 2 The realisation of such benefits implies reduced demand for related clinical services.
In the UK, routine HPV vaccination of girls aged 12-13 years in school started in 2008, together with a 3-year 'catch-up' programme for girls up to 18 years of age, designed to expand the immunised cohort and reduce the lag time to the benefit from vaccination.
3 Uptake rates for the three doses in Scotland are almost 90% of girls routinely immunised at school and 65.5% in the catch-up programme, 4 with an equitable uptake by deprivation score. 5 At the time of this study, women became eligible for cervical screening in Scotland at the age of 20 years. Women offered immunisation in the catch-up programme therefore became eligible for screening in 2010. Scottish data from the catch-up cohort shows a reduced prevalence of HPV 16/18 in women aged 20 (from 29.8 to 13.6%), 7 and also of high-risk HPV types 31, 33, and 45, suggesting cross-protection. 7 A significant reduction in CIN 1 (relative risk, RR 0.71), CIN 2 (RR 0.5), and CIN 3 (RR 0.45) was observed in fully vaccinated women compared with unvaccinated women. 8 Furthermore, there is a reduction of HPV 16/18 in unvaccinated 20 year olds whose peers were vaccinated. 7 Although this is encouraging, reduced HPV and CIN prevalence has implications for screening. We demonstrated that the predictive values of abnormal cytology for CIN have reduced in women who have been immunised, with a concomitant significant increase in the referral value by 38% (i.e. the number of women referred to colposcopy on the basis of abnormal cytology to detect a case of CIN 2+). 9 To inform colposcopy service provision as part of a national programme, we measured changes in the referral and colposcopy activity patterns at a population level using routinely collected data in a cohort of women offered catch-up HPV vaccination. We aimed to monitor the pattern of new referrals to colposcopy, rates of interventions, the positive predictive value (PPV) of colposcopic impression for high-grade CIN, the negative biopsy rate, and the rate of default among young women with increasing rates of HPV vaccination over a period of observation.
Methods
We conducted an observational study using national data. Up to 6 June 2016, the eligible population for the Scottish Cervical Screening programme was women aged 20-60 years, with 3-yearly screening using liquid-based cytology. Referral to colposcopy is based on a single high-grade result or repeated low-grade or borderline nuclear abnormalities. HPV testing is not used for the screening or triage of low-grade disease. Colposcopy data are collected routinely for all women referred to colposcopy in NHS Scotland via the National Colposcopy Clinical Information and Audit System (NCCIAS). This is a web-based system that includes women referred to colposcopy with either abnormal cytology from the screening programme or on clinical grounds (with no cytology or normal cytology). Information is episode based and includes patient demographics, appointment details (including attendance/default), clinical data including indication for referral (e.g. abnormal cytology, clinical signs and symptoms), colposcopy assessment and findings, biopsy results, cytology results, treatment methods, and the follow-up management plan. Data entry and quality checks are conducted locally, and the data are routinely used to produce clinical correspondence for referring practitioners and the women themselves, to monitor colposcopy performance for the British Society for Colposcopy and Cervical Pathology (BSCCP) accreditation, 10 and to benchmark key performance indicators as part of the quality assurance for Scottish colposcopy services.
We obtained an NCCIAS data extract from NHS Scotland Information and Statistics Division (ISD) that contained the records for all women whose date of birth was on or after 1 January 1985, and who were referred to colposcopy in Scotland in the period 2008-2014, inclusive. The data were anonymised by ISD. The analysis was restricted to those referred for colposcopy at the age of 20 or 21 years, in order to increase the likelihood of women being seen at colposcopy following their initial cervical screen. The performance of colposcopy was assessed by calculating the sensitivity, specificity, PPV, and negative predictive value (NPV) with the definitive histology result. Women with normal colposcopy were assumed to have no disease at the time of examination. Performance was calculated at two different cut-offs of disease outcome: for CIN2+ and for any grade of CIN. Evidence of a linear change in performance indicators and proportions over all time points was assessed by logistic regression. As a number of models were run, an adjustment for multiple testing, using the Benjamini-Hochberg false discovery rate procedure, was applied separately to each table, to the traditionally used significance cut-off point of alpha = 0.05. This leads to stricter criteria for declaring statistically significant results, and the clinical significance of all results was also considered. All statistical analysis was conducted in R 3.1 (R Core Team 2015). (Table 1) . There was a non-significant downward trend in the proportion referred with an abnormal screening smear (2008/9, 1294, 91.0%; 2013/14, 758, 90.3%; linear trend P = 0.03). Although the absolute numbers declined, the proportion with borderline nuclear abnormalities (BNAs) and low-grade dyskaryosis increased, with a corresponding reduction in the proportion of women referred with highgrade dyskaryosis and any grade of dyskaryosis (2008/9, 41.2%; 2013/14, 30.7%; linear trend P = 0.01). The number of women with high-grade dyskaryosis had more than halved from 533 in 2008/9 to 233 in 2013/14, although the 2008/9 figure is potentially an outlier. Women are also referred to colposcopy outwith the screening programme for clinical reasons. For these women, there was an increase in the proportion referred to colposcopy with a clinically suspicious cervix (2008/9, 1.6%; 2013/14, 3.1%; linear trend P = 0.02), but there was no change in the presence of any specific gynaecological symptom [e.g. intermenstrual bleeding (IMB) or postcoital bleeding (PCB); Table 1 ]. Table 2 shows data from 7013 individual women aged 20-21 years who had a colposcopy examination during 2008-2014. The full data set is available in Table S1 . The number of women with a colposcopically normal cervix, Referral cytology result Table 3 shows the performance of colposcopy to predict or exclude CIN. The PPV of colposcopy for CIN2 or worse (CIN2+) on biopsy decreased significantly, from 79% in 2008/9 to 67% in 2013/14 (linear trend P = 0.0002), although with the main change associated with 2013/14. The PPV of colposcopy for any grade of CIN (CIN+) on biopsy was relatively unchanged: 84% in 2008/9 and 80% in 2013/14 (linear trend P = 0.32). We did not find any significant change in the sensitivity and specificity of colposcopy to predict CIN2+ on biopsy over the period assessed.
Results

Pattern of referrals
Rates of diagnostic and therapeutic interventions
(n = 1422) (n = 1513) (n = 1295) (n = 1306) (n = 997) (n = 839) P ReferralTotal (n = 1294) (n = 1403) (n = 1187) (n = 1195) (n = 887) (n = 758)
Negative biopsy rate
During 2008-2014, 5535 women aged 20-21 years had a biopsy performed at the colposcopy visit. The negative 
Default from first attendance at colposcopy rate
The majority of the women (93.9%) attended their first colposcopy appointment within 3 months from their date of referral (or date of screening cytology reported on SCCRS). Table 4 shows the attendance and default rates for colposcopy. The proportion of women who did not attend without prior warning (DNA), calculated as the proportion of all women given an appointment, decreased significantly over time (2008/9, 26.0%; 2013/14, 17.6%; linear trend P < 0.0001).
Discussion
Main findings
The results from this ecological population-based study indicate a reduction in the absolute numbers of young women referred to colposcopy from the catch-up cohort offered HPV immunisation. The time frame of the data collection and the size of the effect suggests that this is likely to be associated with HPV vaccination. Previous studies have confirmed the reduction in HPV vaccine type genotypes and performance of cytology as a consequence of immunisation, [5] [6] [7] [8] [9] flagging up the need to review the screening pathway. This is the first population-based study to demonstrate reduced colposcopy activity and performance. We have also confirmed the reported changes in colposcopy performance linked to vaccine status. 11 The majority of HPV vaccine impact studies have focused on the effect on circulating HPV types, 6, 7, 12, 13 as well as screening cytology. 2, 8, 9, 12 The sentinel surveillance system in the USA reported a 26% reduction in HPV 16/18 associated CIN2+ following HPV vaccination, 14 but did not discuss the impact on service provision.
Clearly, in countries with both vaccination and cervical screening, the screening programme criteria for referral to colposcopy must be reviewed to ensure the effective delivery of colposcopy services and to minimise the disbenefits of over-diagnosis in low-risk women. Employing such a risk-stratified approach may further reduce the colposcopy workload, with implications for service delivery including recruitment and retention of staff, maintaining quality and performance, and ensuring equitable access for women.
Although the numbers are small, the proportion of women referred to colposcopy with gynaecological signs has increased. Gynaecology services allocate patients with 'red flag' symptoms of cervical cancer to different services, which may include colposcopy, general gynaecology, gynaecology/oncology, or sexual health. The increase in symptomatic women may be the result of optimising spare colposcopy clinic capacity by accepting referrals that could otherwise be seen at other clinics, rather than being driven by an increased suspicion of cervical cancer in this low-risk cohort. This would maintain skills and the use of colposcopy clinic capacity, time, and staffing, relieving pressure on other gynaecology services. The increase in cytology sampling at colposcopy could have two explanations: either there has been a relative increase in the number of women with symptoms who are due for screening or colposcopists are managing their own clinical uncertainty by repeating cytology. The latter is not evidence-based and should be addressed at clinic and national guideline level to avoid unnecessary procedures that are unlikely to contribute effectively to patient management.
Importantly, we are reporting on women who meet the criteria for colposcopy referral (including persistent lowgrade disease) compared with single abnormalities reported in the screened population. 8 Before vaccination, the risk of associated CIN with persistent low-grade changes was sufficient to warrant investigation at colposcopy. In our analysis, we identified an increase in women referred with no identifiable CIN. This corroborates our previous observation that the referral value of cytology increased in women who have been immunised, 9 strengthening the need to review referral criteria to reflect the reduced risk of underlying CIN. National direction from the screening programme may be necessary to address the issues of referral criteria, capacity, and clinical management highlighted by our results.
Strengths and limitations
Our study uses nationwide colposcopy data on all women referred to colposcopy in NHS Scotland; the organised nature of the screening programme advocates that national guidelines are followed, mitigating to an extent the influence of individualised practice. Lead colposcopists are responsible for data entry and quality management of data within NCCIAS.
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This is an ecological study, but although there is no linkage from NCCIAS to the national immunisation record, the magnitude of the change in activity at colposcopy, the temporal relationship with the implementation of immunisation, and the effect reported from screening data in Scotland indicate that these effects are attributable to HPV immunisation. [7] [8] [9] Although the completion of three doses has been reported at over 65% in the catch-up cohort, this was highest in girls vaccinated in school (80% uptake) and lower (30% uptake) in those who had left school. 5 Our data come from the catch-up programme, and the maximum effect, when women vaccinated in the school programme attend screening, is yet to be seen.
Our results could be affected by a number of possible biases. Following the death of a media celebrity in the UK in 2009, there was an increase in the uptake of screening and detection of CIN and cervical cancer, particularly in younger women, which was not subsequently sustained. 16 This would account for the number of abnormalities detected in 2009 compared with previous or subsequent years. There was national standardisation of the referral criteria for low-grade dyskaryosis from a single to two consecutive low-grade cytology tests in 2012, bringing two of the larger health boards into alignment with the practice of the remaining 12 Scottish boards. In 2013, cytology terminology changed so 'BNA with koilocytes' were classified as low-grade dyskaryosis. This will have altered the reporting profile but would not explain the increase in BNA reports. We have previously reported that the number of young women participating in screening has not decreased in recent years, so fewer cases does not reflect lower attendance. 9 The HPV vaccination campaign prompted the dissemination of information on HPV and immunisation for girls and parents, including in the national media. The effect of these factors cannot be measured in this study.
Interpretation
The demand for colposcopy services is influenced by a number of factors, including the target screening population, the screening test used, and the referral criteria. Other influences include vaccine-uptake rates, the type of vaccine, and the dosing schedule, as well the health-seeking behaviours of the population. Colposcopy requirements of the screening programme will fall and spare capacity at colposcopy carries a cost to the health service. Using colposcopy services to manage gynaecological conditions may not be the most efficient use of a specialist resource, but may allow colposcopists to see sufficient numbers of women to maintain their pattern recognition and operative skills, and assure the quality of the service. 10 In the UK, the key performance indicator is the positive predictive value (PPV) of colposcopy with the lowest acceptable PPV of colposcopy for high-grade CIN set at 65%. 17 Our data indicate that the PPV of colposcopy in women aged 20-21 years is now just above this benchmark, indicating that the cut-off for referral to colposcopy needs review. Furthermore, this threshold may well be breached with an increasingly vaccinated population. We do not yet have data to support alternative strategies based on vaccination status. This would require robust linked data on vaccination status to implement safely.
In Scotland, the peak prevalence of CIN3 is found in the 25-29 year old age band, 18 which accounts for almost a third of all cases per annum. The proportion of cases of CIN3 diagnosed in the 20-24 year old age band represents the second highest proportion, at 21-24%. As the prevalence of CIN3 continues to fall over the next 5 years in both age groups, we need to ensure that any rationalisation of colposcopy services considers the need to maintain the necessary expertise to diagnose and treat women as part of cervical cancer prevention. Although there are a number of new technologies that aim to be an adjuvant to traditional colposcopy, 19,20 their performance also relies on the prevalence of CIN in the referral population.
It is inevitable that the anticipated potential of vaccination to reduce cervical cancer in the future will reduce secondary prevention activity; service planning needs to address this foreseeable change. Should colposcopy training and staffing be allowed to undergo attrition, or should the existing clinical capacity be used for other patient groups who would benefit from the same clinical expertise? Whilst colposcopy skills are transferrable to other lower genital tract sites, this will require upskilling for the staff who currently only deal with cervical disease.
Conclusion
A reduction in colposcopy workload is likely to be related to the HPV immunisation. A review of service provision (including referral criteria) that takes into account the increasing number of vaccinated women who will enter screening is required to ensure the continued delivery of an effective colposcopy service.
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